Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.57 |
| ▸ | XDH | P47989 | 6/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17155460 | 0.88 | AAK1 (0.58) | AAK1XDHSLC22A12 | |
| SCHEMBL9477443 | 0.86 | AAK1 (0.51) | AAK1XDHSLC22A12 | |
| SCHEMBL7695663 | 0.86 | AAK1 (0.51) | AAK1XDHSLC22A12 | |
| SCHEMBL7695665 | 0.86 | AAK1 (0.51) | AAK1XDHSLC22A12 | |
| SCHEMBL28986747 | 0.84 | AAK1 (0.49) | AAK1XDHSLC22A12 | |
| SCHEMBL31573 | 0.83 | XDH (0.69) | AAK1XDHSLC22A12 | |
| SCHEMBL13182575 | 0.82 | XDH (0.53) | XDHSLC22A12 | |
| SCHEMBL2344031 | 0.82 | XDH (0.53) | XDHSLC22A12 | |
| SCHEMBL31019133 | 0.82 | XDH (0.53) | XDHSLC22A12 | |
| SCHEMBL392560 | 0.81 | MAOB (0.47) | AAK1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109293597-B | Preparation method of febuxostat | 安徽省庆云医药股份有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-110078668-B | Phenyl imidazole XOR inhibitor, preparation and application | 华南理工大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-109293597-B | Preparation method of febuxostat | 安徽省庆云医药股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-109293597-B | Preparation method of febuxostat | 安徽省庆云医药股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-106279024-A | A kind of xanthine oxidoreductase inhibitors and preparation method and application | 华南理工大学 | 2017-01-04 | — | — | CN | disclosed |
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| CN-103068807-B | By using the preparation method of phenyl substituted heterocycle derivative of coupling process of palladium compound | TEIJIN PHARMA LTD. (JP) | 2016-05-25 | — | — | CN | disclosed |
| US-8952174-B2 | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8952174-B2 | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-102333765-B | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst | TEIJIN PHARMA LTD | 2015-01-14 | — | — | CN | disclosed |
| US-7612108-B2 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2009-11-03 | — | — | US | disclosed |
| EP-1783116-B1 | 2-PHENYLPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2009-08-26 | — | — | EP | disclosed |
| CN-101389352-A | Agent for treating or preventing digestive ulcer | ASTELLAS PHARMA INC (JP) | 2009-03-18 | — | — | CN | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | ASTELLAS PHARMA INC. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| CN-101010300-A | 2-phenylpyridine derivative | ASTELLAS PHARMA INC (JP) | 2007-08-01 | — | — | CN | disclosed |
| EP-1783116-A1 | 2-PHENYLPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1783124-A1 | 2-PHENYLTHIOPHENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275950-A1 | 2-Phenylpyridine Derivative | NLRP3, XDH, UACA | AAK1 1983/4885XDH 2/4885SLC22A12 745/4885 |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | AAK1 2320/4885XDH 1/4885SLC22A12 1172/4885 |
| US-20080027048-A1 | Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy | XDH, UACA, NUDT1 | AAK1 2805/4885XDH 1/4885SLC22A12 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.